| Name | Title | Contact Details |
|---|
Patient populations deserve better care. We believe this is possible when physicians are empowered with actionable real-time data to make the most informed medical decisions possible. Alio Medical is medical technology company focused on providing peace of mind to dialysis patients through advanced remote monitoring. Alio provides wireless, remote, noninvasive monitoring of end stage kidney disease (ESKD) patients undergoing hemodialysis. Alio monitors dialysis patient blood flow by capturing and transmitting multimodal sensor data at regular intervals using quantitative analysis of optical, mechanical, acoustic, and thermal data related to blood flow and the composition of the blood itself. Alio remote monitoring utilizes a wearable device, the SmartPatch, placed over the patient`s vascular access graft to gather data and transmit it to a Hub located in the patient`s home. The Hub relays this raw data to the Alio Cloud where it is processed and analyzed utilizing Alio`s proprietary algorithms, developed using data collected pre- and post-dialysis in clinical centers in the US and UK. Alio clinically actionable data is accessed by the clinical team via a web-based data portal and the clinical team is alerted if an abnormality in any of a patient`s metrics is detected. Alio is designed to allow the dialysis patient healthcare team to partner effectively and enjoy simpler care coordination as well as more effective management of their patient`s health.
Microbot Medical was founded with the vision of pioneering Micro Invasive Surgery, transforming one of the biggest trends in healthcare - Minimally Invasive Surgery (estimated to be close to $20B by 2015); the company will provide transformational micro invasive technologies with the accuracy of robots and automated instruments to assist physicians in targeting the disease site with exquisite precision. Microbot will solve one of the largest unmet needs in the medical field, where morbidity as a result of surgery is more frequently due to trauma involved in gaining access to the area to perform the intended procedure rather than from the procedure itself. Through its unique platforms, Microbot will reach multiple surgical spaces, capitalizing on the fact that minimally invasive techniques have been applied to most of the surgical specialties. Microbot`s ViRob platform is an Autonomous Advancing Micro Robot (AAMR), less then 1mm in diameter, which has the ability to advance (forward/backward) within cavities/lumens (such as the typical human body`s veins and arteries). The TipCat platform is a self-propelled, flexible, see & treats endoscope/catheter. It is comprised of a series of interconnected balloons that provide forward and backward motion while allowing for a working channel to be available during the procedure. In developing its platforms, the company is focusing on multi-disciplinary platform of products.
Sebacia is a clinical-stage` private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia’s goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia’s microparticles technology was invented and licensed from Rice University` and the dermatology applications were further developed with researchers from and the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth` Georgia
For 25 years, Q'Straint has remained focused on one vision: to develop the world's most effective wheelchair passenger safety solutions for public and private transportation. Today, Q'Straint is a global company with a local network of representatives
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss. The company has developed the Earlens® Contact Hearing Solution, which directly vibrates the eardrum with a tiny lens in order to activate the natural hearing process. This revolutionary, nonsurgical hearing solution delivers the broadest bandwidth available today and superior sound quality. The Earlens® Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. We believe that people with hearing loss shouldn`t have to think about their hearing in everyday situations. Earlens was designed specifically to address the sound quality and speech understanding complaints that are common among hearing aid wearers and contribute to non-compliance. We make every Earlens device custom-fit for each patient`s unique anatomy and hearing needs, while offering modern features such as Bluetooth streaming.